
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) – Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Tuesday, November 17th. HC Wainwright analyst B. Folkes forecasts that the biotechnology company will post earnings per share of ($0.49) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.55) EPS, Q4 2027 earnings at ($0.57) EPS, FY2027 earnings at ($2.14) EPS, FY2028 earnings at ($2.67) EPS, FY2029 earnings at ($1.95) EPS and FY2030 earnings at ($1.62) EPS.
A number of other brokerages also recently commented on ENTA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, October 11th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $20.00.
Read Our Latest Research Report on Enanta Pharmaceuticals
Enanta Pharmaceuticals Stock Performance
NASDAQ:ENTA opened at $8.23 on Thursday. The company’s 50-day moving average is $11.68 and its two-hundred day moving average is $13.03. Enanta Pharmaceuticals has a 12-month low of $8.10 and a 12-month high of $17.15.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last announced its earnings results on Monday, November 16th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.09). Enanta Pharmaceuticals had a negative net margin of 108.33% and a negative return on equity of 59.48%. The firm had revenue of $12.87 million during the quarter, compared to analyst estimates of $14.62 million.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Jupiter Topco LLC acquired a new stake in shares of Enanta Pharmaceuticals in the second quarter worth approximately $53,252,000. Janus Henderson Group PLC grew its holdings in Enanta Pharmaceuticals by 1.5% in the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock valued at $47,717,000 after purchasing an additional 54,396 shares during the period. BlackRock Inc. purchased a new stake in Enanta Pharmaceuticals in the second quarter valued at approximately $47,304,000. ADAR1 Capital Management LLC purchased a new stake in Enanta Pharmaceuticals in the second quarter valued at approximately $19,603,000. Finally, Spruce Street Capital LP purchased a new stake in Enanta Pharmaceuticals in the second quarter valued at approximately $15,873,698. 94.99% of the stock is currently owned by hedge funds and other institutional investors.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.
Read More
- Five stocks we like better than Enanta Pharmaceuticals
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
